These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9818206)

  • 1. Angiotensin II receptor antagonists and treatment of hypertension and renal disease.
    Perico N; Remuzzi G
    Curr Opin Nephrol Hypertens; 1998 Sep; 7(5):571-8. PubMed ID: 9818206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?
    Taylor AA
    Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):643-8. PubMed ID: 11496059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J; Praga M; de Vinuesa SG
    Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.
    Weir MR; Henrich WL
    Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):403-11. PubMed ID: 10926177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?
    Doggrell SA
    Expert Opin Pharmacother; 2002 Nov; 3(11):1543-56. PubMed ID: 12437489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease.
    Ram CV; Vergne-Marini P
    Curr Hypertens Rep; 1999 Oct; 1(5):431-5. PubMed ID: 10981102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic measures in proteinuric nephropathy.
    Praga M
    Kidney Int Suppl; 2005 Dec; (99):S137-41. PubMed ID: 16336567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
    von Vigier RO; Zberg PM; Teuffel O; Bianchetti MG
    Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection.
    Appel GB; Appel AS
    Prog Cardiovasc Dis; 2004; 47(2):105-15. PubMed ID: 15586351
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination ACEI and ARB therapy: additional benefit in renoprotection?
    Taal MW; Brenner BM
    Curr Opin Nephrol Hypertens; 2002 Jul; 11(4):377-81. PubMed ID: 12105385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
    Weber MA
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
    Zoja C; Donadelli R; Corna D; Testa D; Facchinetti D; Maffi R; Luzzana E; Colosio V; Bertani T; Remuzzi G
    Am J Kidney Dis; 1997 Feb; 29(2):254-64. PubMed ID: 9016898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Angiotensin II receptor blockers: current status and future prospects].
    Corvol P; Plouin PF
    Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valsartan and the kidney: present and future.
    Mann JF
    J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S37-40; discussion S41-3. PubMed ID: 10028953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney.
    Thurman JM; Schrier RW
    Am J Med; 2003 May; 114(7):588-98. PubMed ID: 12753883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.